InHealth Molecular Imaging Limited

Unaudited Financial Statements for the Year ded 30 September 2022

FRIDAY



433 30

30/06/2023 OMPANIES HOUSE:

Contents

| Company Information | | • | | | 1 |
|-----------------------------------|--|---|-----|-----|-------|
| Directors' Report | | | | | 2 |
| Balance Sheet | | | • • | | 3 |
| Statement of Changes in Equity | | | | . • | . 4 |
| Notes to the Financial Statements | | | | | 5 - 6 |

Company Information

Directors: R J Bradford

A G Searle

S J Scott

Registered Office: Beechwood Hall

Kingsmead Road

High Wycombe

Buckinghamshire

HP11 1JL

Registered Number: 06135533 (England and Wales)

Bank of Scotland

4th Floor

25 Gresham Street

London

EC2V 7HN

Directors' Report

The Directors present their report and Financial Statements for the Company for the year ended 30 September 2022.

Principal activity

The principal activity of the Company is the provision of healthcare services and solutions using Positron Emission Tomography (PET) CT scanning technologies. A strategic review is currently ongoing regarding future market opportunities.

Business review

Revenue for the year for the Company was £nil (2021: £nil) generating an operating profit of £188,000 (2021: £nil) relating to release of historic accrual position.

The Company is non-trading and has not traded during the year or subsequent to the year end and is waiting for responses to tenders for future services to be confirmed.

Directors

The Directors who held office during the year and up to the date of signing the Financial Statements were as follows:

R J Bradford

A G Searle

D M Petrie (resigned 7 February 2022)

S J Scott (appointed 7 February 2022)

Political donations

The Company made no political donations (2021: £nil).

Small companies' regime

The Company's Directors' Report has been prepared in accordance with the provisions applicable to entities subject to the small companies' regime.

Approved by the Board and signed on its behalf by:

R J Bradford Director

27 June 2023

Balance Sheet at 30 September 2022

| | Note | 2022 £000 | 2022 £000 | 2021 £000 | 2021 £000 |
|--|------|--------------|--------------|--------------|--------------|
| Current assets Debtors | 2 | 1,849 | | 1,849 | |
| | - | 1,849 | | 1,849 | |
| Creditors: amounts falling due within one year | . 3 | • | | (188) | |
| Net current assets | ٠. | | 1,849 | | 1,661 |
| Total assets less current liabilities | | | 1,849 | | 1,661 |
| Net assets | | | 1,849 | . · · | 1,661 |
| Capital and reserves Profit and loss account | | | 1,849 | | 1,661 |
| Shareholders' funds | | | 1,849 | _ | 1,661 |

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of Financial Statements.

The Company's Financial Statements have been prepared in accordance with the provisions applicable to entities subject to the small companies' regime.

In accordance with Section 444 of the Companies Act 2006, the statement of income has not been delivered.

These Financial Statements were approved by the Board of Directors on 27 June 2023 and were signed on its behalf by:

R J Bradford Director

Company registration number: 06135533

The accompanying notes on pages 5 to 6 form part of these Financial Statements.

Statement of Changes in Equity For the Year Ended 30 September 2022

| | Called up share capital £000 | Profit and loss account £000 | Total equity £000 |
|---|---------------------------------------|---------------------------------------|-------------------------|
| Balance at 1 October 2020 | · . • | 1,661 | 1,661 |
| Total comprehensive income for the year | ··· · · · · · · · · · · · · · · · · · | · | |
| Balance at 30 September 2021 | • | 1,661 | 1,661 |
| Total comprehensive income for the year | - | 188 | 188 |
| | · | | |
| Balance at 30 September 2022 | · <u>-</u> | 1,849 | 1,849 |

The notes on pages 5 to 6 form part of these Financial Statements.

Notes to the Financial Statements

(forming part of the Financial Statements)

1 Accounting policies

1.1 Basis of preparation of Financial Statements

InHealth Molecular Imaging Limited is a Company incorporated, domiciled and registered in England, UK. The Company's registered number and registered address can be found on the Company Information page.

The Financial Statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' and the Companies Act 2006.

The preparation of Financial Statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies. Management concluded that estimates and assumptions have no significant effect on the amounts recognised in the Financial Statements.

1.2 Financial reporting standard 101 - reduced disclosure exemptions

In these Financial Statements, the Company has applied the exemptions available under FRS 101 in respect of the following disclosures:

- IAS 1 'Presentation of Financial Statements': Exemption from providing comparative movement schedules for share capital.
- IAS 8 'Accounting Policies, Changes in Accounting Estimates and Errors': Exemption from the disclosure of new or revised IFRSs that have not been amended, as well as the disclosure of their likely impact.
- IAS 24 'Related Party Disclosures': Disclosure exemption for related party transactions entered into between two or more members of a group provided that any subsidiary which is a party of the transaction is wholly owned by such a member.

Taking up these disclosure exemptions is made possible by the inclusion of equivalent disclosures within the consolidated Financial Statements of InHealth UK Holdings Limited, the largest group in which the results of the Company are consolidated.

1.3 Going concern

The Company's business activities, together with the factors likely to affect its future development and position, are set out in the Principal Activity section of the Directors' Report on page 2.

On the basis of their assessment of the Company's financial position the Company's Directors have a reasonable expectation that the Company will be able to continue in operational existence for the foreseeable future. The Directors have no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of the Company to continue as a going concern. Thus they continue to adopt the going concern basis of accounting in preparing the annual Financial Statements.

1.4 Financial instruments

The Company's main financial instruments comprise: trade and other debtors.

Trade and other debtors

Trade and other debtors are recognised initially at fair value. Subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses.

Notes to the Financial Statements (continued)

2 Debtors

| | | 2022 £000 | 2021 £000 |
|--|------|--------------|--------------|
| Amounts falling due after more than one year | | | |
| Amounts owed by group undertakings | | 1,849 | 1,849 |

The amounts owed by group undertakings due after more than one year are repayable 2 years from the balance sheet date. The face value of the loans is £1,849,000 (2021: £nil) at an interest rate of 0% (2021: n/a). These loans are held at fair value of £1,849,000 (2021: £nil).

3 Creditors: Amounts falling due within one year

| 3 | Creditors: Amounts falling due within one ye | ear . | | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |
|-------|--|-------|-------|---------------------------------------|
| | | | 2022 | 2021 |
| | | | €000 | £000 |
| Acc | ruals and deferred income | | | 188 |
| | | • | | |
| 4 | Called up share capital | | e " t | S. 40 |
| | · · · · · · · · · · · · · · · · · · · | | 2022 | 2021 |
| | | | £000 | £000£ |
| Allo | ted, called up and fully paid | | | |
| 1 (20 | 021: 1) Ordinary £1 shares | | • | · |
| | • | | | |

5 Ultimate parent undertaking and parent company of larger group

The ultimate parent undertaking and controlling party is The Damask Trust, the Trustees of which are I H Bradbury and The Embleton Trust Corporation Limited.

The largest Group in which the results of the Company are consolidated is that headed by InHealth UK Holdings Limited, which is incorporated in England and Wales. The smallest Group in which the results of the Company are consolidated is that headed by InHealth Group Limited, which is incorporated in England and Wales. The consolidated Financial Statements of these groups are available to the public and may be obtained from Beechwood Hall, Kingsmead Road, High Wycombe, Buckinghamshire, HP11 1JL.